|Day Low/High||50.86 / 53.73|
|52 Wk Low/High||17.51 / 111.36|
SAN FRANCISCO, June 14, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of Drug...
Jim Cramer says the tech titans are leading the way, but out side of the tech sector, very few stocks are following.
Jim Cramer weighs in on Hasbro, Dropbox, Carlyle Group, Corning, Banco Santander, Goldman Sachs, Edwards Lifesciences, J. Jill and more.
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
SAN FRANCISCO, June 5, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.
Nektar Therapeutics shares got destroyed on Monday. Here is why.
Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation
Abstract presentations highlight potential of NKTR-214 to be combined with multiple I-O and targeted mechanisms in the treatment of cancer
Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.
Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #12 spot from Thermo Fisher Scientific Inc , according to ETF Channel. Below is a chart of Nektar Therapeutics versus Thermo Fisher Scientific Inc plotting their respective rank within the S&P 500 over time (NKTR plotted in blue; TMO plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
New collaboration to explore the potential clinical benefits of two novel and complementary immuno-oncology mechanisms
These names are showing bullish and bearish technical patterns over the past week.
Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.
Stocks finished higher on Wednesday.
Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar's lead...
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
It is premature to think that this market has hit a top until there is further evidence in the price action.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.